The Basics
What Is Psilocybin?
New here? This is your two-minute primer.
Psilocybin is a naturally occurring psychoactive compound found in 200+ species of fungi — commonly called “magic mushrooms.” When ingested, the body converts it to psilocin, which binds to serotonin receptors in the brain and temporarily disrupts the default mode network — the system linked to rumination and rigid thinking. The result is a 4–6 hour experience that researchers now associate with lasting improvements in depression, addiction, and emotional wellbeing.
It is not addictive, has no known lethal dose, and has been used in indigenous healing traditions for over 3,000 years. Despite this, it has been a federal Schedule I substance since 1970. That classification is now under direct challenge from one of the fastest-growing bodies of evidence in modern psychiatry — and a presidential executive order signed April 18, 2026.
The Science
Clinical Research
After decades of prohibition, 102 of the 134+ registered psilocybin trials were started in just the last five years. The results are remarkable — and consistent — across nearly every condition studied.
FDA Pipeline
| Company | Compound | Indication | Status |
|---|
| Compass Pathways | COMP360 (synthetic) | Treatment-Resistant Depression | 3-for-3 Phase 3 · NDA Q4 2026 |
| Cybin / Helus Pharma | HLP003 (deuterated) | Major Depressive Disorder | BT Designation · Phase 3 underway |
| Usona Institute | Psilocybin | MDD | Phase 3 (uAspire) · Piggyback possible |
| AbbVie / Gilgamesh | Bretisilocin (GM-2505) | MDD | Phase 2 · $1.2B acquisition |
| GH Research | Mebufotenin (5-MeO-DMT) | TRD | Phase 3 planned 2026 · 73% remission |
| AtaiBeckley | BPL-003 (intranasal) | TRD | BT Designation · Phase 3 Q2 2026 |
Major Research Institutions
| Institution | Focus | Notable |
|---|
| Johns Hopkins | Depression, addiction, cancer, consciousness | 20+ trials; Center for Psychedelic Research est. 2020; landmark 2006 study that restarted the field worldwide |
| Imperial College London | Brain imaging, depression, mechanisms | World’s first Centre for Psychedelic Research (2019); first modern psilocybin depression trial |
| UCSF Neuroscape | Neuroimaging, neuroplasticity | Psychedelics Division est. 2021; Robin Carhart-Harris directs |
| Yale | Depression, OCD, brain structure | 8 trials; psilocybin causes structural brain changes countering depression |
| Mount Sinai | PTSD, trauma | Centre for Psychedelic Psychotherapy and Trauma Research (2021) |
| VA Palo Alto / Stanford | Veterans with TRD and PTSD | First psilocybin study within the VA system |
| Ohio State | Long-term depression outcomes | 5-year durability follow-up data (2025) |
| Emory University | Anti-aging, longevity, eligibility | 2025 aging study: +50% cell lifespan, +30% mouse survival; 5M+ eligibility estimate |
Landmark Findings
Phase 3 Success — TRD
COMP360 25mg hit its primary endpoint in all three Phase 3 trials (1,000+ patients). COMP005 (June 2025): p<0.001, -3.6 MADRS. COMP006 (Feb 2026): p<0.001, -3.8 MADRS. NDA rolling submission planned Q4 2026.
Compass Pathways IR, 2025–2026
Study details
COMP005: 258 patients, 32 U.S. sites, double-blind RCT. DSMB found no unexpected safety signals.
COMP006: Confirmed in a second independent population. Combined 1,000+ participants.
FDA policy: One pivotal trial is now the default standard — both trials exceeded the bar.
Psilocybin vs. SSRIs (NEJM, 2021)
Head-to-head trial found psilocybin comparable to escitalopram (leading SSRI) for depression, with advantages on several secondary measures including social functioning and emotional processing.
Carhart-Harris et al., NEJM, 2021
5-Year Durability
Two-thirds of participants remained free from depression five years after just two doses of psilocybin with psychotherapy support. Researchers propose the compound triggers lasting “positive behavioral feedback loops.”
Ohio State / Johns Hopkins, 2025
Cancer-Related Distress
A single high dose produced substantial, sustained decreases in depression and anxiety in patients with life-threatening cancer — effects lasting 6+ months. One of the most replicated findings in the field.
Griffiths et al., J Psychopharmacology, 2016
Tobacco Cessation
80% abstinence at 6 months vs. ~35% for best available treatments. Among the highest cessation rates ever recorded in clinical research. 60% still abstinent at 30 months.
Johnson et al., Johns Hopkins
Veterans with Severe TRD
First-in-kind VA pilot: 60% response, 53% remission at 3 weeks. 47% maintained response at 12 weeks. Co-morbid PTSD did not worsen outcomes.
Ellis et al., J Affective Disorders, 2025
Study details
Setting: VA Palo Alto / Stanford. 15 veterans, single 25mg dose, open-label.
12-month follow-up: Durable benefits in a subset. VA announced first-ever psychedelic research funding Jan 2024.
HLP003 for MDD
75% of participants achieved full remission at 4 months after just 2 doses. Shorter session duration than standard psilocybin is a practical clinical advantage.
Cybin/Helus Phase 2, 2024
Alcohol Use Disorder
First randomized controlled trial showed significant reductions in heavy drinking days vs. control. Establishes psilocybin as a potential AUD treatment.
Bogenschutz et al., JAMA Psychiatry, 2022
🔬 Anti-Aging Breakthrough (Emory, 2025)
Psilocin extended human skin and lung cell lifespan by 50%+. Aged mice given monthly doses showed a 30% increase in survival, improved fur quality, reduced oxidative stress, improved DNA repair, and preserved telomere length — targeting multiple hallmarks of aging simultaneously.
Kato et al., npj Aging, July 2025
Full study details
Institutions: Emory University School of Medicine; Baylor College of Medicine.
Lead authors: Kosuke Kato, Louise Hecker, Ali John Zarrabi (Director of Psychedelic Research, Emory).
Cell results: Lung cells: 57% longer to senescence. Skin cells: 51% lifespan increase.
Mouse results: 19-month-old females (~60 human years). 30% survival increase. Healthier fur; regrowth observed.
Key insight: Most body cells express serotonin receptors — psilocybin’s effects may not be limited to the brain.
Quote: “These mice weren’t just surviving longer — they experienced better aging.” — Dr. Zarrabi
Emory news release · Full paper (PMC)
Other Conditions Under Active Study
- PTSD — Compass IND accepted Jan 2026; multiple Phase 2/3 trials recruiting
- OCD — Yale, early positive results
- Anorexia nervosa — Lund University, Johns Hopkins
- Cluster headaches and migraines — Yale / Ceruvia Lifesciences
- Parkinson’s disease mood dysfunction — open-label pilot, 2025
- Opioid use disorder, chronic pain, Alzheimer’s disease — in registration or early trials
- Post-treatment Lyme disease — Johns Hopkins, registered 2023
- End-of-life existential distress — multiple institutions
- Postpartum depression — FDA Breakthrough Therapy Designation granted April 2026
Safety Profile
Established as safe in controlled settings. Oregon’s regulated program reports a 0.15% adverse event rate across 8,500+ clients. Psilocybin is not physically addictive and has no known lethal dose in humans. Common acute effects include transient anxiety, nausea, headache, and temporary blood pressure elevation. Risks increase substantially in uncontrolled settings and without proper screening or trained facilitation.
Law & Policy
Regulation & Legal Landscape
Three states legalized. Fifteen-plus cities decriminalized. A federal executive order now in place. An FDA application coming this year. The path is real.
🔴 Breaking — April 18, 2026
Trump Signs Executive Order on Psychedelic Therapies
The first federal executive action explicitly supporting psychedelic access. Issues National Priority Vouchers for BT-designated drugs, allocates $50M via ARPA-H, directs the DEA to begin rescheduling reviews upon Phase 3 completion, and expands Right to Try applicability. FDA Commissioner Makary: approval could come “in weeks.” Joe Rogan present at signing.
Full EO details & analysis
Key provisions: National Priority Vouchers; $50M ARPA-H matching funds; Right to Try for psychedelics; FDA-DEA-VA data sharing; accelerated rescheduling; expanded compassionate use.
Impact on COMP360: Compass reportedly on initial Priority Voucher list. Rolling NDA Q4 2026. Approval possible late 2026 — 9–12 months earlier than pre-EO estimates.
Sources: Full EO (whitehouse.gov) · NPR · Harvard Law analysis
Federal Status
Psilocybin remains Schedule I under the Controlled Substances Act. FDA has granted Breakthrough Therapy Designation for TRD (Compass, 2019), MDD (Cybin, 2024), and postpartum depression (2026). The April 2026 EO dramatically accelerates rescheduling. One pivotal trial is now the FDA’s default approval standard.
States with Regulated Access
Legal Oregon
Measure 109 (2020). Service centers open since summer 2023. ~16,000 clients served. Adults 21+ in supervised settings. $1,000–$3,000/session; no insurance. HB 2387 (2025) allows medical professionals as facilitators.
Legal Colorado
Prop 122 (2022). First healing center licensed April 2025. 34 licensed centers as of early 2026. Personal cultivation permitted (21+). May expand to DMT/ibogaine/mescaline by June 2026. SB 297 (2025): clemency for past convictions.
Medical New Mexico
SB 219 (2025). Third state; first via legislation (not ballot). Medical program for qualifying conditions. Implementation targeted December 2026.
Decriminalized Jurisdictions
| Jurisdiction | Year | Details |
|---|
| Denver, CO | 2019 | First U.S. city — lowest law enforcement priority |
| Oakland, CA | 2019 | All entheogenic plants and fungi deprioritized |
| Santa Cruz, CA | 2020 | Deprioritized enforcement |
| Washington, D.C. | 2020 | Initiative 81 — entheogenic plants lowest priority |
| Ann Arbor / Detroit, MI | 2020–21 | Decriminalized natural psychedelics by city vote |
| Seattle, WA | 2021 | Lowest law enforcement priority |
| Somerville / Cambridge, MA | 2021–22 | Deprioritized; Easthampton, Northampton followed |
| Olympia, WA | 2024 | Plant-based hallucinogens decriminalized |
| Tacoma, WA | Jan 2025 | Natural psychedelics decriminalized |
| King County, WA | Mar 2026 | Personal psychedelic use deprioritized (Seattle metro) |
Active State Legislation (2025–2026)
- Minnesota HF2906: Would legalize psilocybin therapy and reschedule to Schedule IV. Passed committee with bipartisan voice vote, March 2026.
- Missouri HB 1643: Psilocybin access for end-of-life care, PTSD, MDD, and substance use disorders.
- Texas SB 2308: $50M for FDA-supervised ibogaine clinical trials. Signed by Governor Abbott.
- Arizona: $5M for psilocybin trials; rescheduling trigger bill passed 2025.
- Iowa, Oklahoma, Virginia, Hawaii, Connecticut: Active bills in 2026 session.
- Alaska: Natural Medicine Act filed for potential 2026 ballot initiative.
- 36+ psychedelic-related bills introduced in U.S. state legislatures in the 2025 session alone.
International
- Australia (2023): First country to allow authorized psychiatrists to prescribe psilocybin for TRD.
- New Zealand (2025): Approved for therapeutic use.
- Canada: Special Access Programme for end-of-life distress and TRD (case-by-case basis).
- Jamaica, Brazil, Netherlands, Samoa: Legal or exist in a gray area.
- UN (2025): Commission on Narcotic Drugs voted for first independent expert review of international drug control systems.
Society
Culture & Public Opinion
How America is changing its mind — and the forces driving that change faster than most experts predicted.
Where America Stands
- 23% of U.S. adults support legal psilocybin use (RAND, 2025/2026). This mirrors cannabis support in the mid-1990s — right before the medical marijuana wave swept the country.
- 28% support psychedelic legalization overall (PRRI, 2024). Partisan breakdown: Democrats 36%, independents 31%, Republicans 16%.
- Bipartisan support for supervised therapeutic use in licensed settings is consistently the highest-polling frame across party lines.
- 71% of healthcare professionals express belief in psilocybin’s therapeutic promise — though objective knowledge remains low, revealing a major training gap.
- The Massachusetts 2024 ballot to broadly legalize psychedelics was defeated (57% no) — showing limits of current support for wide-open access without medical framing.
The Cost & Access Problem
The equity challenge: Oregon sessions cost $1,000–$3,000 out of pocket. Insurance doesn’t cover it. Facilitator training runs $15,000–$20,000+. FDA approval of synthetic psilocybin could enable insurance reimbursement — potentially transforming access overnight. An Emory study (2024) estimated 5M+ Americans qualify for psilocybin therapy. 85% of clinical trial participants to date have been non-Hispanic White, underscoring urgent need for diversity in research and access.
Cultural Forces
- Michael Pollan’s How to Change Your Mind (2018 book, 2022 Netflix) brought psychedelic research into mainstream American consciousness at scale.
- Podcasts: Joe Rogan Experience, Tim Ferriss Show, and Huberman Lab have reached tens of millions. Rogan was present at Trump’s April 2026 EO signing.
- Veterans as catalysts: Heroic Hearts Project (1,200+ veteran families), American Legion, and Disabled American Veterans have made psychedelic reform genuinely bipartisan. The 2024 NDAA authorized DoD psychedelic research.
- Paul Stamets and Fantastic Fungi (Netflix) reached audiences that scientific journals never could — normalizing the conversation at the kitchen table level.
- Media coverage surged 2020–2024. Psilocybin leads all psychedelic substances in mainstream media mentions by a wide margin.
Who’s Who
Notable Figures
The scientists, advocates, and cultural voices who built this field — and the ones shaping where it goes next.
Scientific Leaders
Roland R. Griffiths, Ph.D.
Johns Hopkins · 1946–2023
The father of the modern psychedelic renaissance. His 2006 landmark study on psilocybin-occasioned mystical experiences restarted a field dormant for 40 years. Published 400+ journal articles. Founded the Johns Hopkins Center for Psychedelic and Consciousness Research. Passed away October 2023.
Robin Carhart-Harris, Ph.D.
UCSF · Formerly Imperial College London
Founded the world’s first Centre for Psychedelic Research at Imperial College (2019). Led the landmark NEJM psilocybin vs. SSRI trial. Named TIME “100 Next” and one of the world’s top 31 medical scientists (The Times, 2020). Brain imaging pioneer. Now Ralph Metzner Distinguished Professor at UCSF.
Matthew W. Johnson, Ph.D.
Johns Hopkins University
Expert on addiction medicine and psychedelic therapy. Key researcher on psilocybin for tobacco cessation (80% abstinence), alcohol use disorder, and depression. Associate Professor of Psychiatry and Behavioral Sciences.
David Nutt, DM, FRCP
Imperial College London
Professor of Neuropsychopharmacology. Longtime evidence-based drug policy advocate. Former UK government drug advisor, famously fired for publishing data showing psilocybin is safer than alcohol. Co-founded the Centre for Psychedelic Research.
Alan Davis, Ph.D.
Ohio State University
Lead author on multiple landmark psilocybin depression studies. Directs the Center for Psychedelic Drug Research and Education at Ohio State. Led the 5-year durability follow-up study (2025).
Ali John Zarrabi, M.D.
Emory University
Director of Psychedelic Research at Emory Psychiatry. Co-investigator on the landmark 2025 anti-aging study. Leading Emory’s expansion into psilocybin beyond depression into longevity and systemic biology.
Cultural & Advocacy Figures
Paul Stamets
Mycologist · Author · Entrepreneur
The world’s most recognized mycologist and public advocate for psilocybin mushrooms. Author of seven books on fungi. Founder of Fungi Perfecti (Host Defense). Featured in Netflix’s Fantastic Fungi. Recipient of the National Mycologist Award and Gordon & Tina Wasson Award. A Star Trek: Discovery character bears his name. His Joe Rogan (#1035) and Tim Ferriss appearances are among the most-viewed media on psilocybin. Advocates for psilocybin as “People’s Medicine.”
Michael Pollan
Author · Journalist
Author of How to Change Your Mind (2018) — the bestselling book credited with mainstreaming psychedelic research. Netflix documentary followed in 2022. Brought rigorous, accessible journalism to the psychedelic renaissance at exactly the right cultural moment.
Rick Doblin, Ph.D.
Founder, MAPS
Founded the Multidisciplinary Association for Psychedelic Studies. Decades of advocacy built the legal and research infrastructure that benefits all psychedelic science today. His 30-year push through MDMA clinical trials paved every road psilocybin researchers now travel.
Amanda Feilding
Founder, Beckley Foundation
Pioneered psychedelic research partnerships with Imperial College and institutions worldwide for 25+ years through the Beckley Foundation (est. 1998). A key connector between science and policy reform long before it was mainstream.
Tim Ferriss
Author · Investor · Podcaster
Provided $2+ million in seed funding for Johns Hopkins’ psychedelic research center. Used his platform to normalize psychedelic research conversations, reaching millions of listeners before this was a culturally acceptable topic.
Industry Leaders
Kabir Nath
CEO, Compass Pathways
Steering Compass through 3-for-3 Phase 3 success and toward Q4 2026 NDA submission. Advocates for FDA-approved synthetic psilocybin as the path to insurance coverage and democratized access.
Doug Drysdale
CEO, Cybin / Helus Pharma
Led development of HLP003, a deuterated psilocybin analog engineered for shorter sessions and more practical clinical delivery. Secured $500M to fund Phase 3 trials.
Markets
Financials & Public Markets
Big pharma has entered the room. A billion-dollar acquisition, hundreds of millions raised, a sector-wide rally on executive action, and analyst price targets as high as $70. Here’s the money.
Public Company Snapshot (April 2026, approximate)
| Company | Ticker | Price | Mkt Cap | 52-Wk | Key Catalyst |
|---|
| Compass Pathways | CMPS (Nasdaq) | ~$9.85 | ~$890M | $2.25–$10.21 | NDA Q4 2026; +28% on Trump EO; 3-for-3 |
| AtaiBeckley | ATAI (Nasdaq) | ~$5.50 | ~$400M | $2.00–$7.50 | BPL-003 Phase 3; Guggenheim PT $16 |
| Cybin / Helus Pharma | HELP (Nasdaq) | ~$5.50 | ~$275M | $4.29–$9.83 | HLP003 Phase 3 data Q4 2026; $500M secured |
| GH Research | GHRS (Nasdaq) | Volatile | ~$500M | Wide | Mebufotenin Phase 3 2026; 73% remission Phase 2 |
| PSIL ETF | PSIL (NYSE) | — | ETF | — | Psychedelic sector basket; ~+25% YTD |
All psychedelic companies are pre-revenue. Not investment advice. Verify current prices independently.
Major Financial Moves
💰 AbbVie Acquires Bretisilocin — $1.2B
In August 2025, AbbVie (~$300B market cap) acquired Gilgamesh Pharmaceuticals’ bretisilocin — a short-acting psilocybin analog in Phase 2 for MDD — for up to $1.2 billion. The first billion-dollar psychedelic deal by major pharma.
AbbVie press release, Aug 2025
💰 Compass Raises $341M
February 2026: Compass raised ~$341 million through a public offering and warrant exercises, extending its runway into 2028. Funds cover NDA submission and pre-commercial preparation.
Compass Pathways IR, Feb 2026
💰 Cybin → Helus + $500M Deal
Cybin rebranded as Helus Pharma (Nasdaq: HELP) in December 2025 and secured a $500 million deal with High Trail Special Situations to fund HLP003 Phase 3.
Cybin/Helus corporate filings, Dec 2025
💰 AtaiBeckley Merger
Atai Life Sciences and Beckley Psytech merged in November 2025, forming AtaiBeckley (Nasdaq: ATAI). Backed by Peter Thiel and Christian Angermayer. Advancing BPL-003 for TRD toward Phase 3.
Company announcements, Nov 2025
Analyst Sentiment
- Compass (CMPS): 11 analysts rate Buy. Average PT $21.75; high PT $70 (HC Wainwright). CMPS surged 28% on Trump EO. Stock up ~113% over 12 months.
- AtaiBeckley (ATAI): Guggenheim raised PT $11 → $16 post-EO. Deutsche Bank initiated Buy.
- Cybin/Helus (HELP): “Strong Buy” consensus. Phase 3 data Q4 2026 is the next major sector catalyst alongside Compass NDA.
- Sector: The Trump EO drove a sector-wide rally. Analysts frame the NDA filing + FDA Priority Review as a binary event defining the sector’s near-term trajectory.
Disclaimer: All publicly traded psychedelic companies are pre-revenue, loss-making biotechs at high risk of dilution, clinical failure, and regulatory setbacks. This section is informational only. Not investment advice. Consult a qualified financial advisor.
History
How We Got Here
From the first city to decriminalize to a presidential executive order in seven years — the key moments that brought psilocybin from the fringe to the front page.
2019–2020
May 2019: Denver becomes first U.S. city to decriminalize psilocybin.
Nov 2019: FDA grants Breakthrough Therapy Designation to Compass Pathways’ COMP360 for TRD.
Sept 2020: Johns Hopkins launches Center for Psychedelic and Consciousness Research ($17M funding).
Nov 2020: Oregon passes Measure 109 — first state to legalize regulated psilocybin services. D.C. decriminalizes via Initiative 81.
2021–2022
2021: NEJM publishes Carhart-Harris trial: psilocybin matches leading SSRI for depression. UCSF Neuroscape and Mass General psychedelic centers launch.
Nov 2022: Colorado passes Proposition 122 — second state to approve regulated psychedelic therapy.
2023
Summer: Oregon’s first psilocybin service centers open. Legal psychedelic therapy in America begins.
Sept: Johns Hopkins largest naturalistic survey (2,833 respondents): persistent mental health improvements.
Oct: California SB 58 vetoed by Newsom. Australia becomes first country to allow psilocybin prescriptions.
2024
Jan: VA announces first psilocybin/MDMA research funding since the 1960s.
Mar: Cybin receives FDA Breakthrough Therapy Designation for CYB003 (now HLP003) for MDD. Phase 2: 75% remission at 4 months.
Aug: FDA rejects MDMA therapy (Lykos) for PTSD — cautionary tale for the field.
Nov: Massachusetts psychedelic ballot defeated (57% no). Emory: 5M+ Americans eligible for psilocybin therapy if FDA-approved.
2025
June: Compass COMP005 Phase 3 primary endpoint met (p<0.001). New Mexico SB 219 passes — third state, first via legislation.
July: Emory anti-aging study: psilocin extends cell lifespan 50%+; aged mice live 30% longer. Published in npj Aging.
Aug: AbbVie acquires Gilgamesh’s bretisilocin for up to $1.2 billion. Big pharma enters psychedelics.
Nov: AtaiBeckley merger. 5-year depression follow-up: two-thirds still depression-free.
Dec: Cybin rebrands as Helus Pharma; secures $500M deal.
2026 — Current
Jan: FDA accepts Compass IND for PTSD. GH Research clinical hold lifted.
Feb: COMP006 Phase 3 primary endpoint met (p<0.001, -3.8 MADRS). Compass now 3-for-3. Targets Q4 NDA. Raises $341M.
Mar: Minnesota HF2906 psilocybin therapy bill passes committee. King County, WA deprioritizes psychedelics.
Apr 18: Trump signs Executive Order fast-tracking psychedelic FDA review. $50M ARPA-H. National Priority Vouchers. CMPS +28%.
Apr: Psilocybin analogue receives BT Designation for postpartum depression — a new indication.
Upcoming: Q3: COMP006 durability data. Q4: NDA filing. Colorado expansion. New Mexico launch (Dec).
2027–2031 (Projected)
Late 2026/2027: Potential first FDA approval of psilocybin — timeline accelerated 9–12 months by EO and Priority Vouchers.
2027: New Mexico program operational. Cybin/Helus Phase 3 data. GH Research Phase 3 data.
2028–30: If approved: DEA rescheduling, insurance coverage, rapid state expansion, workforce scale-up.
2033–37: Modeling projects majority of U.S. states will have some form of legal psychedelic access.
What’s Next
The Path Forward
The most consequential 18 months in the history of psychedelic medicine are underway. Here’s what to watch.
FDA Approval — The Critical Path
Compass has completed three successful Phase 3 trials and plans a rolling NDA submission for Q4 2026. With National Priority Vouchers from the Trump EO, review could be expedited dramatically. An optimistic but now plausible scenario: first FDA approval by late 2026.
Critically, psilocybin companies are pursuing drug-only approval (not drug-plus-therapy), simplifying the path that contributed to MDMA’s rejection. Cybin/Helus’ shorter-acting formulation may have additional practical clinical advantages.
If FDA Approves…
- Insurance coverage would likely follow, transforming access for an estimated 5M+ eligible Americans.
- DEA rescheduling from Schedule I. Johns Hopkins recommends Schedule IV (similar to prescription sleep aids).
- Rapid state expansion as legal ambiguity dissolves and state programs proliferate.
- Workforce at scale — thousands of trained facilitators needed across the country.
- Medicaid debates — 17M+ Medicaid beneficiaries have clinical depression. Coverage equity will be the defining access question.
Open Questions
- Dosing: No consensus on optimal dose across conditions and populations.
- Therapy vs. drug alone: How much benefit depends on psychotherapy? Key for insurance models.
- Long-term safety at scale: More data needed from larger, longer, more diverse populations.
- Equity: $1,000–$3,000/session out-of-pocket; 85% non-Hispanic White trial enrollment. Requires active correction.
- Federal-state tension: Schedule I status creates ongoing legal uncertainty for practitioners until rescheduling.
- Quality control: Product consistency, accurate dosing, and adequate participant screening as programs scale.
References
Sources & Further Reading
Government & Regulatory
Key Peer-Reviewed Studies
- Carhart-Harris et al. (2021). Psilocybin vs. Escitalopram. NEJM, 384(15), 1402–1411.
- Davis et al. (2021). Psilocybin-Assisted Therapy for MDD. JAMA Psychiatry, 78(5), 481–489.
- Griffiths et al. (2016). Psilocybin and cancer distress. J Psychopharmacology, 30(12), 1181–1197.
- Ellis et al. (2025). Psilocybin for veterans with severe TRD. J Affective Disorders, 369, 381–389.
- Hinkle et al. (2024). Adverse events in classic psychedelic studies. JAMA Psychiatry, 81, 1225–1235.
- Kato et al. (2025). Psilocybin extends cell lifespan and improves survival in aged mice. npj Aging, 11(55).
- Compass Pathways COMP005 and COMP006 Phase 3 results (2025–2026)
- Bogenschutz et al. (2022). Psilocybin for Alcohol Use Disorder. JAMA Psychiatry.
Policy Trackers
Public Opinion
Financial & Industry
Cultural & Institutional